Benzinga | Dec 29, 2021 06:46AM EST

Stipulation Of Partial Judgment In Favor Of Liquidia Filed In Hatch-Waxman Litigation

MORRISVILLE, N.C., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Patent No. 9,604,901 ('901 patent) in the on-going litigation under the Hatch-Waxman Act (Hatch-Waxman). Under the stipulation of partial judgment, UTC has agreed to the entry of judgment of Liquidia's non-infringement of the '901 patent based on the Court's construction of certain terms in the patent. UTC has preserved its appellate rights with respect to the '901 patent in the event the Court's construction of those terms is reversed. With this stipulation of partial judgment, only U.S. Patent No. 9,593,066 ('066 patent) will now serve as a basis for the on-going regulatory stay for final approval of YUTREPIA(tm) (treprostinil) inhalation powder by the U.S. Food and Drug Administration (FDA).